- To investigate the costs and effects of long-term oral anticoagulant treatment after myocardial infarction.
- Cost-effectiveness analysis, based on a randomized, double-blind, placebo-controlled trial.
Sixty Dutch hospitals.
- A total of 3404 hospital survivors of acute myocardial infarction randomized within a median period of 4 days after discharge to either oral anticoagulant treatment or placebo.
The mean follow-up was 37 months.
- Oral anticoagulant treatment aimed at a target international normalized ratio of 2.8 to 4.8. Main Outcome Measurements. - Costs of hospital stay during readmissions, costs related to major cardiologic interventions, and costs of oral anticoagulant treatment.
- The costs of oral anticoagulant treatment were estimated at 394 Dutch guilders (Dfl) per patient-year (Dfl1=US $0.58).
Placebo patients stayed 18 830 days in the hospital compared with 15 083 days for anticoagulation patients.
Average costs per patient of medical care during follow-up were estimated at Dfl 10 784 for placebo patients and Dfl 9878 for anticoagulation patients.
- Costs of long-term anticoagulant treatment are outweighed by the costs of prevented clinical events.
Mots-clés Pascal : Infarctus, Myocarde, Anticoagulant, Coût, Chimiothérapie, Traitement, Homme, Economie santé, Activité biologique, Voie orale, Appareil circulatoire pathologie, Cardiopathie coronaire, Myocarde pathologie, Long terme
Mots-clés Pascal anglais : Infarct, Myocardium, Anticoagulant, Costs, Chemotherapy, Treatment, Human, Health economy, Biological activity, Oral administration, Cardiovascular disease, Coronary heart disease, Myocardial disease, Long term
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0263882
Code Inist : 002B02F07. Création : 01/03/1996.